Asbury-Casto v. GlaxoSmithKline, Inc.

352 F. Supp. 2d 729, 2005 WL 112094
CourtDistrict Court, N.D. West Virginia
DecidedJanuary 19, 2005
DocketCIV.A.5:04 CV 111
StatusPublished
Cited by4 cases

This text of 352 F. Supp. 2d 729 (Asbury-Casto v. GlaxoSmithKline, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. West Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Asbury-Casto v. GlaxoSmithKline, Inc., 352 F. Supp. 2d 729, 2005 WL 112094 (N.D.W. Va. 2005).

Opinion

MEMORANDUM OPINION AND ORDER DENYING PLAINTIFF’S MOTION TO REMAND

STAMP, District Judge.

I. Procedural Histoi'y

On August 31, 2004, the plaintiff, Sherry Asbury-Casto, commenced this action in the Circuit Court of Brooke County, West Virginia. The defendant, GlaxoSmithK-line, Inc., timely removed the action to this Court pursuant to 28 U.S.C. § 1332. On October 4, 2004, the defendant filed a motion to stay this action pending transfer to the United States Judicial Panel on Multi-district Litigation (“MDL Panel”). On October 15, 2004, the MDL Panel entered a conditional transfer order assigning this case to the In re Paxil Products Liability Litigation, MDL-1574. On November 1, 2004, the plaintiff filed a motion to vacate the conditional transfer order, which is currently pending before the MDL Panel. On November 8, 2004, the parties filed an agreed order staying the first order and notice regarding discovery and scheduling in this action pending resolution of the issue of transfer by the MDL Panel. This Court approved and entered the parties’ agreed order on that same date.

On October 27, 2004, the plaintiff filed a motion to amend her complaint. This Court granted the plaintiffs motion on December 2, 2004. The plaintiff also filed a motion to remand and a memorandum in support, to which the defendant responded with a memorandum in opposition. The plaintiff did not reply to the defendant’s response.

The plaintiffs motion to remand is now before this Court. After reviewing the parties’ memoranda and the applicable law, this Court finds that defendant’s removal was proper and the plaintiffs motion to remand should be denied.

II. Facts

The plaintiff brings this action individually and on behalf of all consumers within the State of West Virginia who, since 1994, purchased the prescription medication Paxil, a drug manufactured and marketed by the defendant. The plaintiffs complaint alleges that the defendant “fraudulently induced consumers to purchase its pharmaceutical Paxil by advertising nonexistent benefits and concealing and trivializing known deadly and life altering risks.” Compl. ¶ 1. She claims that “[t]he defendant knew, or should have known *731 that Paxil, as designed and manufactured, would cause severe health risks in individuals taking the drug, including, but not limited to: severe withdrawal symptoms; addiction; and, increased risk of suicide.” PL’s Mem. in Supp. of Mot. for Remand to State Court at 2 (citing Compl. ¶¶ 18-21). Based on these allegations, she brings claims against the defendant for violations of the West Virginia Consumer Credit and Protection Act and for unjust enrichment. She seeks compensatory and punitive damages, as well as “[Restitution of all purchase costs Plaintiffs paid for Paxil and disgorgement of Defendant’s profits.” Compl. 11F.

Defendant removed the case to this Court under 28 U.S.C. § 1332, which provides federal jurisdiction when diversity of citizenship is present. Both parties agree that there is complete diversity under the statute, as plaintiff is a citizen of West Virginia and defendant is a North Carolina corporation with its principal place of business in Pennsylvania. Defendant further contends that, although the plaintiff specifically disclaims damages in excess of $75,000.00 in the ad damnum clause of the complaint, her statement is not determinative, and the amount in controversy exceeds the jurisdictional requirement. In her motion to remand, plaintiff denies that the amount in controversy requirement is satisfied. Plaintiff contends that the burden of proof is on the defendant to show that the damages could exceed $75,000.00, and that the defendant has failed to do so.

III. Applicable Law

When a defendant seeks to remove a case from state court to a federal district court pursuant to 28 U.S.C. § 1441(a), the federal court must be able to exercise original jurisdiction over the matter. See 28 U.S.C. § 1441(a)(1). Under 28 U.S.C. § 1332(a), the federal district courts have original jurisdiction over cases between citizens of different states where the amount in controversy exceeds $75,000.00, exclusive of interest and costs. See 28 U.S.C. § 1332(a).

A defendant wishing to remove a case to federal court based upon § 1332 must offer “competent proof’ that the jurisdictional requirements are met. See Chase v. Shop ‘N Save Warehouse Foods, 110 F.3d 424, 427 (7th Cir.1997). This proof must be by a preponderance of the evidence. See, e.g., Singer v. State Farm Mut. Auto. Ins., 116 F.3d 373, 377 (9th Cir.1997). “To satisfy this burden, a defendant must offer more than a bare allegation that the amount in controversy exceeds $75,000.00.” Sayre v. Potts, 32 F.Supp.2d 881, 886 (S.D.W.Va.1999). If federal jurisdiction is doubtful, remand is necessary. See Mulcahey v. Columbia Organic Chem. Co., Inc., 29 F.3d 148, 151 (4th Cir.1994).

Although courts strictly construe the statute granting removal jurisdiction, see Doe v. Allied Signal, Inc., 985 F.2d 908, 911 (7th Cir.1993), the court is not required “to leave common sense behind” when determining the amount in controversy. Mullins v. Harry’s Mobile Homes, 861 F.Supp. 22, 24 (S.D.W.Va.1994). When the amount in controversy is not apparent on the face of the plaintiffs complaint, the federal court must attempt to ascertain the amount in controversy by considering the plaintiffs cause of action as alleged in the complaint and any amendments thereto, the notice of removal filed with a federal court, and other relevant materials in the record. See 14C Charles A. Wright & Arthur R. Miller, Federal Practice and Procedure § 3725 at 73 (3d ed.1998). However, the court is limited to examining only evidence that was available at the moment the petition for removal was filed. See Chase, 110 F.3d at 428.

*732 The Supreme Court of Appeals of West Virginia has stated that “the value of a lawsuit is not determined definitively by the ad damnum, clause.” State ex rel. Strickland v. Daniels, 173 W.Va.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Wine v. Stone Energy Corporation
N.D. West Virginia, 2018
Strawn v. AT & T MOBILITY, INC.
513 F. Supp. 2d 599 (S.D. West Virginia, 2007)
Grubbs v. Westfield Insurance
430 F. Supp. 2d 563 (N.D. West Virginia, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
352 F. Supp. 2d 729, 2005 WL 112094, Counsel Stack Legal Research, https://law.counselstack.com/opinion/asbury-casto-v-glaxosmithkline-inc-wvnd-2005.